Scholarlink

Background <p>Polycystic ovarian syndrome (PCOS) is a common gynaecological and endocrinological disorder that causes anovulatory infertility affecting 4–10% of women of reproductive age. Although current therapeutic options exist, many are accompanied by adverse effects, underscoring the need for safer and more effective alternatives. 7-Hydroxyflavone (7-HF), a natural flavonoid, has demonstrated notable biological properties; however, its therapeutic potential in PCOS remains unexplored. The current study aimed to explore the possible role of 7-HF in treating letrozole-induced PCOS in rats.</p> Methods <p>PCOS was induced in Female Wistar Rats by the administration of letrozole (1&#xa0;mg/kg, p.o.) for 21&#xa0;days. After induction, rats were treated with 7-Hydroxyflavone at various doses (5, 10 and 15&#xa0;mg/kg) and metformin (300&#xa0;mg/kg) for 14 consecutive days.</p> Result <p>Letrozole-induced PCOS was characterized by disrupted estrous cycle, increased body and ovarian weights, cystic ovarian follicles, altered metabolic and hormonal levels, enhanced oxidative stress (elevated LPO, SOD; reduced GSH), and elevated inflammatory markers (TNF-alpha and IL-6). Treatment with 7-Hydroxyflavone significantly mitigated these alterations, restored normal estrous cycles and hormonal balance, reduced oxidative stress and inflammation, and improved ovarian histology in a dose-dependent manner.</p> Conclusion <p>This study provides the first evidence that 7-Hydroxyflavone effectively mitigates letrozole-induced PCOS manifestations in rats, likely through its antioxidant, anti-inflammatory, and endocrine-modulating effects. These findings support the therapeutic potential of 7-HF as a novel candidate for PCOS management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic potential of 7-hydroxyflavone in letrozole-induced polycystic ovarian syndrome via regulation of oxidative stress, inflammation, hormonal and biochemical dysregulation

  • 期刊论文

  • 发表日期：

    2026年1月19日

查看全文
  • Ashish Tale,
  • Deepak Lokwani,
  • Komal Mandade,
  • Sachin Borikar,
  • Sangameshwar Kanthale,
  • Satish Shelke,
  • Shirish Jain

摘要

Background

Polycystic ovarian syndrome (PCOS) is a common gynaecological and endocrinological disorder that causes anovulatory infertility affecting 4–10% of women of reproductive age. Although current therapeutic options exist, many are accompanied by adverse effects, underscoring the need for safer and more effective alternatives. 7-Hydroxyflavone (7-HF), a natural flavonoid, has demonstrated notable biological properties; however, its therapeutic potential in PCOS remains unexplored. The current study aimed to explore the possible role of 7-HF in treating letrozole-induced PCOS in rats.

Methods

PCOS was induced in Female Wistar Rats by the administration of letrozole (1 mg/kg, p.o.) for 21 days. After induction, rats were treated with 7-Hydroxyflavone at various doses (5, 10 and 15 mg/kg) and metformin (300 mg/kg) for 14 consecutive days.

Result

Letrozole-induced PCOS was characterized by disrupted estrous cycle, increased body and ovarian weights, cystic ovarian follicles, altered metabolic and hormonal levels, enhanced oxidative stress (elevated LPO, SOD; reduced GSH), and elevated inflammatory markers (TNF-alpha and IL-6). Treatment with 7-Hydroxyflavone significantly mitigated these alterations, restored normal estrous cycles and hormonal balance, reduced oxidative stress and inflammation, and improved ovarian histology in a dose-dependent manner.

Conclusion

This study provides the first evidence that 7-Hydroxyflavone effectively mitigates letrozole-induced PCOS manifestations in rats, likely through its antioxidant, anti-inflammatory, and endocrine-modulating effects. These findings support the therapeutic potential of 7-HF as a novel candidate for PCOS management.